Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era-Reference-Cited by-同舟云学术

Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era

Published:2019-03 Issue: Volume:74 Page:35-42
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Tucci Marcello,Caffo Orazio^ORCID,Buttigliero Consuelo,Cavaliere Carla,D'aniello Carmine,Di Maio Massimo,Kinspergher Stefania,Maines Francesca,Rizzo Mimma,Rossetti Sabrina,Veccia Antonello,Scagliotti Giorgio Vittorio,Facchini Gaetano^ORCID

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference80 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. The current state of hormonal therapy for prostate cancer;Hellerstedt;CA Cancer J Clin,2002

3. Androgen receptor variation affects prostate cancer progression and drug resistance;McCrea;Pharmacol Res,2016

4. Targeting bone physiology for the treatment of metastatic prostate cancer;Autio;Clin Adv Hematol Oncol,2013

5. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N. Engl. J Med,2010

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p‐STAT3 in prostate cancer;The Prostate;2023-10-12

2. The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report;Frontiers in Oncology;2023-09-27

3. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC;European Journal of Medicinal Chemistry;2023-02

4. Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis;Current Oncology;2022-12-04

5. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses;The Oncologist;2022-09-19